Nebenwirkungen · DuoResp Spiromax
DuoResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder · Abschnitt 4.8 · PDF-Seite 11
HOS-215213 · Präparat HOS-155404
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing´s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Increased susceptibility to infections and impairment of the ability to adapt to stress may also occur. Effects are probably dependent on dose, exposure time, concomitant and previous steroid exposure and individual sensitivity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-24T17:52:00Z · SHA-256 42079bf4b69044dc4d633d260c46172c183d9e017cb9bfa60f9313d810771afa · Passage 59cf134ca2a9444f50e0386ef5270abbe3ce3b977eb606418dab6dcc594c8bba · Zeichen 4833–5449 im Abschnitt